Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03636204 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
A Phase 1 study of Healthy and Frontotemporal Dementia, sponsored by Alector.
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 8
- Study locations
NCT03636204: Completed Phase 1 study of Healthy and Frontotemporal Dementia, sponsored by Alector.
NCT03636204 is a Phase 1 study of Healthy and Frontotemporal Dementia that has completed, run by Alector. The registered enrollment target is 64 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03636204, a Phase 1 study of Healthy and Frontotemporal Dementia, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 8
- Study locations
Study Summary
A first in human phase 1 study in healthy volunteers and participants with Granulin (GRN) mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics
Primary Outcome
Incidence of adverse events and dose limiting Adverse Events during the DLAE observation period and/or study treatment periods.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL AL001
Study Locations (8)
Other
- Sunnybrook Health Sciences Centre - Toronto
- University College London - London
Alabama
- University of Alabama - Birmingham
California
- UCSF - San Francisco
Florida
- Study site - Orlando
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- University of Pennsylvania - Philadelphia
Ontario
- Lawson Health Research Institute, St. Joseph's - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2018-09-14 |
| Est. Completion | 2019-12-31 |
| Phase | Phase 1 |
What the finished NCT03636204 record still lists
NCT03636204 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Healthy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03636204 lists 8 locations in 7 states (Other, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT03636204 about?
NCT03636204 is a clinical study titled "A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation". A first in human phase 1 study in healthy volunteers and participants with Granulin (GRN) mutation causative of frontotemporal dementia (FTD) to assess AL001 safety, tolerability, pharmacokinetics, and pharmacodynamics
What is the current status of trial NCT03636204?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2018-09-14. Estimated completion is 2019-12-31.
What conditions does trial NCT03636204 study?
This clinical trial studies the following conditions: Healthy, Frontotemporal Dementia.
What interventions are being tested in trial NCT03636204?
The interventions under investigation include: Placebo (OTHER), AL001 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03636204?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03636204 being conducted?
This trial has 8 study locations across Alabama, California, Florida, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03636204's enrollment target sits among peer trials
64 353rd of 1090 higher than 731 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI